Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

2519 - QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: results from the tBRCAmut subset


20 Oct 2018


Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research


Cytotoxic Therapy;  Targeted Therapy

Tumour Site

Ovarian Cancer


Kathleen Moore


Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285


K.N. Moore1, A.A. Secord2, M. Geller3, D.S. Miller4, N.G. Cloven5, G.F. Fleming6, A.E. Wahner Hendrickson7, M. Azodi8, P. DiSilvestro9, A. Oza10, M. Cristea11, J.S. Berek12, J.K. Chan13, B.J. Rimel14, Y. Li15, K. Luptakova16, R. Clark16, U.A. Matulonis17, B.J. Monk18

Author affiliations

  • 1 Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma, 73104 - Oklahoma City/US
  • 2 Gynecologic Oncology, Duke University Medical Center, Duke Cancer Institute, Durham/US
  • 3 Obstetrics, Gynecology And Women's Health, University of Minnesota Medical School, Minneapolis/US
  • 4 Obstetrics & Gynecology, University of Texas Southwestern Medical Center, 75390-8576 - Dallas/US
  • 5 Gynecologic Oncology, Texas Oncology - FortWorth, Fort Worth/US
  • 6 Gynecologic Oncology, The University of Chicago Medicine, 60637-1470 - Chicago/US
  • 7 Medical Oncology, Mayo Clinic, 55905 - Rochester/US
  • 8 Obstetrics, Gynecology & Reproductive Sciences, Smillow Cancer Hospital at Yale and Yale University, New Haven/US
  • 9 Gynecologic Oncology, Women and Infants Hospital, Providence/US
  • 10 Medical Oncology And Hematology, University Health Network and Princess Margaret Cancer Centre, Toronto/CA
  • 11 Medical Oncology & Therapeutics Research, City of Hope National Medical Center, Duarte/US
  • 12 Obstetrics & Gynecology, Stanford Women's Cancer Center, Stanford/US
  • 13 Gynecologic Oncology, Sutter Health, San Francisco/US
  • 14 Obstetrics And Gynecology, Cedars-Sinai Medical Center, West Hollywood/US
  • 15 Biostatistics, TESARO, Inc., Waltham/US
  • 16 Clinical Science, TESARO, Inc., Waltham/US
  • 17 Medical Oncology, Harvard Medical School, Boston/US
  • 18 Division Of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix Creighton University School of Medicine at St. Joseph's Hospital, 85013 - Phoenix/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2519


Therapeutic options in late line ROC offer limited efficacy, especially for pts who are considered platinum (plat) resistant (res) or refractory (ref). Pts whose cancers harbor BRCA mutations (BRCAmut) have been included in poly (ADP-ribose) polymerase inhibitor (PARPi) trials and derived modest benefit from treatment (ORR ≈25% for plat-res and 0-14% for plat-ref pts). QUADRA evaluated niraparib monotherapy in ROC pts regardless of their plat and biomarker status.


Eligible pts received treatment with single agent niraparib in 4th or later line of therapy. Pts were evaluated for BRCAmut and HRD status (MyChoice HRD Test). Pts received niraparib 300 mg once daily until progression; treatment emergent adverse events (AEs) were managed with dose reduction to 200 or 100 mg. The primary endpoint was ORR per RECIST v1.1.


463 pts were treated. Median age was 65 years (range: 29-91). 162 pts were plat ref (defined as progression within 28 days of the last dose of plat); 152 plat res (defined as less than 6 months between last dose of plat and subsequent progression); 118 plat sensitive; 31 unknown. Results in HRD+ pts have been presented at a prior congress. We focus here on the tBRCAmut (both germline and somatic) PARPi-naïve subgroup. ORR for 4th line or later, PARPi-naïve tBRCAmut pts (n = 55) was 31% (95% CI: 19-45), including 18 plat-sensitive pts (ORR 39%), 21 plat-res pts (ORR 33%), and 16 plat-ref pts (ORR 19%). The combined ORR in the plat-res and -ref pts (n = 37) was 27%. The median DOR among all tBRCAmut pts was 9.2 months, with an estimated 43% of responding pts maintaining their response at 24 months. In the entire study cohort, 197 pts (42.5%) experienced a serious AE (SAE) and 91 pts (19.7%) a treatment-related SAE. The most frequent treatment-emergent SAEs were gastrointestinal disorders (19.9%), thrombocytopenia (8.4%), small intestinal obstruction (6.6%), and vomiting (5.1%).


Niraparib demonstrated meaningful and durable responses among the difficult-to-treat patient population, including platinum resistant and refractory tBRCAmut patients.

Clinical trial identification


Legal entity responsible for the study

Tesaro, Inc.


Tesaro, Inc.

Editorial Acknowledgement

Writing and editorial support, funded by Tesaro, Inc. (Waltham, MA, USA) and coordinated by Ted Paunescu, PhD of TESARO, Inc., was provided by Nicole Renner, PhD and Dena McWain of Ashfield Healthcare Communications (Middletown, CT, USA).


K.N. Moore: Honorarium and served on advisory boards: Tesaro, Genentech Roche, Clovis, Astra Zeneca (for agents not involved in the SOLO-a Study), Immunogen, VBL Therapeutics, Janssen. M. Geller: Advisory Role, Speakers' bureau & Research funding: Tesaro Inc. D.S. Miller: Advisory role: Eisai, ImmunoGen, Tesaro, Clovis Oncology, Genentech, AstraZeneca, Guardant Health, Alexion. Speakers' bureau: Genentech, Clovis; Research funding: Tracon, AstraZeneca, Tesaro, Janssen, Aeterna Zentaris, Genentech, Pfizer, Aprea AB, ImmunoGen, Takeda, Xenetic Biosciences. N.G. Cloven: Employment: Texas Oncology. G.F. Fleming: Research funding: Corcept Therapeutics. P. DiSilvestro: Advisory role: Tesaro, AstraZeneca; Research funding: AstraZeneca, Tesaro, Abbvie, Genentech, Roche, Janssen. A. Oza: Steering Committees for PARPi trials: Tesaro, Clovis, AstraZeneca; Honoraria: Intas Pharma. M. Cristea: Research funding: Trovagene. J.S. Berek: Advisory role: Atara Biotherapeutics; Research funding: Tesaro. J.K. Chan: Advisory role: Roche/Genentech, AstraZeneca, Janssen Oncology, Clovis, Mateon, Biodesix, Tesaro; Spearkers' bureau and Honoraria: Roche/Genentech, AstraZeneca, Clovis, Tesaro. Y. Li, K. Luptakova, R. Clark: Employment and stock and other ownership interests: Tesaro Inc. U.A. Matulonis: Advisory role: Merck KGaA, AstraZeneca, Immunogen, Tesaro, Genentech. B.J. Monk: Advisory role: GSK, Merck, Tesaro, Roche/Genentech, AstraZeneca,Gradalis, Advaxis, Verastem, Cerulean Pharma, Amgen, Vermillion, Immunogen, Bayer, NuCana BioMed, Insys Therapeutics, Clovis, Oxigene, Pfizer, Mateon, Precision, Perthera, Biodesix, Abbvie, Myriad, Incyte; Spearkers' bureau: Roche/Genentech, AstraZeneca, Janssen, Clovis, Tesaro; Honoraria: GSK, Merck, Tesaro, Roche/Genentech, AstraZeneca, Gradalis, Advaxis, Veraste, Cerulean, Amgen Vermillion, Bayer, NuCana BioMed, Insys Therapeutics, Clovis, Oxigene, Pfizer Mateon, Precision, Perthera, Biodesix, Abbvie, Myriad, Incyte, Janssen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.